Ira Perszyk, MD
Ophthalmology · Bellingham, WANPI 1508278268
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,654 of the $17,482 with a category attached, or 78.1%. 23 manufacturers reported payments, led by AbbVie at 31.4% of the total. Reporting peaked in 2024 at $3,934 and has fallen 65.3% since, to $1,366 in 2025. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 270 payments — averaging $64.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Sight Sciences, Inc.$3K
- Ivantis, Inc$2K
- Alcon$2K
- Glaukos Corporation$2K
- Sun Pharmaceutical Industries Inc.$972
- plus $2K from 17 others
What the payments were for
- Consulting fees$1,5009%
- Travel & lodging$2,23013%
- Food & beverage$13,65478%
- Education$981%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 85 | $5,488 |
| Sight Sciences, Inc. | 43 | $2,650 |
| Ivantis, Inc | 11 | $2,225 |
| Alcon | 35 | $2,076 |
| Glaukos Corporation | 26 | $1,814 |
| Sun Pharmaceutical Industries Inc. | 18 | $972 |
| Harrow Eye, LLC | 5 | $373 |
| Bausch & Lomb Americas Inc. | 9 | $291 |
| Aerie Pharmaceuticals, Inc. | 8 | $264 |
| Amgen | 3 | $189 |
| Genentech USA, Inc. | 2 | $151 |
| Tarsus Pharmaceuticals, Inc. | 2 | $141 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $137 |
| NEW World Medical,inc. | 1 | $130 |
| Eyepoint US, Inc. | 1 | $128 |
| Rxsight Inc | 2 | $121 |
| Iridex Corporation | 3 | $80 |
| Oyster Point Pharma, Inc. | 4 | $78 |
| Biotissue Holdings Inc. | 3 | $62 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $60 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Thea Pharma Inc. | 1 | $17 |
| Omeros Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$2,449
- XEN GLAUCOMA TREATMENT SYSTEM$1,839
- OMNI(R) SURGICAL SYSTEM (US)$1,685
- XEN$1,284
- SION SURGICAL INSTRUMENT$432
- CEQUA$375
- BROMSITE$375
- XELPROS$375
- DURYSTA$351
- iStent inject W$350
- Clareon$285
- Rhopressa$258
- Rocklatan$258
- AcrySof IQ PanOptix UV IOL$150
- AcrySof IQ VIVITY$150
- SIMBRINZA$137
- TEPEZZA$137
- VABYSMO$130
- Ahmed Glaucoma Valve$130
- Kahook Dual Blade$130
How this compares
$17,482 in reported general payments places this provider in the 90th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 94 | $35,488 |
| RocklatanNetarsudil Mesylat/Latanoprost | 43 | $28,008 |
| VyzultaLatanoprostene Bunod | 43 | $23,970 |
| RestasisCyclosporine | 15 | $20,906 |
| XiidraLifitegrast | 20 | $19,233 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 67 | $16,342 |
| CombiganBrimonidine Tartrate/Timolol | 39 | $16,105 |
| RhopressaNetarsudil Mesylate | 32 | $15,372 |
| Prednisolone Acetate | 320 | $14,753 |
| ProlensaBromfenac Sodium | 31 | $10,458 |
| Alphagan PBrimonidine Tartrate | 19 | $9,217 |
| Latanoprost | 616 | $9,021 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $8,302 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 431 | $7,567 |
| Brimonidine Tartrate | 226 | $7,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $5,488 | $81,716167 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $264 | $43,38075 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $291 | $43,20363 claims |
| AlconSimbrinza, Azopt | $2,076 | $12,62337 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $137 | $12,43443 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 428 ophthalmology providers in Washington.
Other ophthalmology in Bellingham
- Eric SubongBellingham$13K
- Amador SubongBellingham$5K
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Todd SchneidermanSilverdale$200K
- Jennifer ChaoSeattle$188K
- Mark KontosSpokane Valley$175K
- Audrey RostovBellevue$155K
- John SamplesOlympia$115K
- Barbara SmitSpokane$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.